Skip to main content

Table 3 Demographics and clinical characteristics of patients with ICI-related MG and those with idiopathic MGa

From: Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature

Variable

ICI-related MG

iMG [26, 28,29,30, 32, 50]

Mean age (years)

71 ± 9.7

60.0 ± 18.8

Female gender (%)

35%

59%

MGFA classification

 I

12%

52%

 II

22%

43%

 III

12%

3%

 IV

6%

2%

 V

45%

0%

Time from first symptom to Class IV/V

1–60 days (Median: 7 days)

2–3 years

Overlap with myositis/myocarditis

42%

0.9%

Antibodies

 Anti-AChR

66%

83.2%

 Anti-striated muscle

67%

36%b

 Anti-MuSK

3%

2.3%

  1. aAbbreviations: ICI immune checkpoint inhibitors, MG myasthenia gravis, iMG, idiopathic myasthenia gravis, MGFA myasthenia gravis foundation of America, Anti-AChR Anti-Acetylcholine receptor, Anti-MuSK Anti-muscle specific kinase. Numbers are rounded to the nearest whole number
  2. bFor patients with non-thymomatous MG